Hochschule Institute Medizin Institut für Biometrie und Registerforschung

Institut für Biometrie und Registerforschung

Das Institut für Biometrie und Registerforschung entwickelt methodische und statistische Ansätze und wendet diese an auf medizinische Daten um Ursachen, Prävention und Behandlung von Krankheiten zu verstehen. Zusätzlich wird ein Registerforschungsprogramm etabliert, das alle Aspekte der Nutzung von Registern für die Forschung umfasst, einschließlich des Designs von Registern und von klinischen Studien mit Registerdaten, Methoden der Kopplung mehrerer Register und der Durchführung von klinischen Studien mit Registern.

Mitarbeiter des Instituts haben Expertise in Design und Auswertung von klinischen Beobachtungsstudien und bevölkerungsbezogenen Studien, einschliesslich der Modellierung und Prädiktion von Risiken für Spätfolgen der Krebsbehandlung, der Evaluation prädiktiver Marker für personalisierte Medizin, der Bewertung von Langzeitrisiken für die Gesundheit nach der Exposition mit ionisierender Strahlung für diagnostische und therapeutische Zwecke, des Designs von klinischen Studien mit Registerdaten, und der Synthese und Translation von Evidenz aus epidemiologischen Studien in Empfehlungen für individuelle Risikoabschätzung und klinische Praxis.

Aktuelles

Stellenangebote

Wir suchen ab sofort eine(n) Doktorand*in Biostatistik für ein Projekt zu prädiktiven Markern für die personalisierte Brustkrebsbehandlung. Details gibt es hier.

Veröffentlichungen

Van der Willik KD, Hauptmann M, Jóźwiak K, Vinke EJ, Ruiter R, Stricker BH, Compter A, Ikram A, Schagen SB. Trajectories of cognitive performance prior to cancer diagnosis: a population-based study. In press.

Teepen JC, Kok JL, Kremer LC, Tissing WJ, Van den Heuvel-Eibrink MM, Loonen JJ, Bresters D, Van der Pal HJ, Versluys B, Van Dulmen-den Broeder E, Nijsten T, Hauptmann M, Hollema N, Dolsma WV, Van Leeuwen FE, Ronckers CM, DCOG-LATER Study Group. Long-term risk of skin cancer among childhood cancer survivors: a DCOG-LATER cohort study. J Natl Cancer Inst 2019; 111(8): 845–853.

 

Leitung
Wissenschaftliche Mitarbeiter*innen
Forschungsprojekte

Statistische Methoden für die Bewertung später Nebenwirkungen von Radiotherapie

Weil die Zahl der Patienten, die eine Krebsdiagnose langfristig überlebt haben, stark steigt, ist es wichtig, die Spätfolgen der Krebstherapie zu verstehen, im Besonderen zweite Tumore durch die Exposition gesunden Gewebes während der Radiotherapie. Ein genaue Schätzung dieses Risikos ist essentiell für das Einbeziehen von Risikoprädiktionen in den medizinischen Entscheidungsprozess bei Diagnose und nach der Behandlung. In epidemiologischen Studien zum Risiko für einen zweiten strahleninduzierten Tumor durch momentan die räumliche Verteilung der Strahlenexposition während der Radiotherapie nicht einbezogen, obwohl man Davon effizientere und weniger verzerrte Schätzungen der Dosis-Wirkungs-Beziehung und bessere Risikoprädiktionen für die klinische Anwendung erwartet. In diesem durch die Dutch Cancer Society  geförderten Projekt entwickeln und beschreiben Doktorand Sander Roberti und Dr. Viet Nguyen statistische Methoden zur Schätzung des Risikos für einen Zweittumor aufgrund der Dosisverteilung im Zielorgan. Die Methoden wurden hinsichtlich Effizienz und Bias miteinander verglichen. Risikoprädiktionen wurden von diesen Methoden abgeleitet. Dazu werden Daten der BRIGHT-Studie benutzt, die das Brustkrebsrisiko nach einem Hodgkin-Lymphom anhand der dreidimensionalen Verteilung der Strahlendosis in der Brust dieser Patienten untersucht. Diese Dosisverteilung wurde retrospektiv geschätzt (Russell et al. 2017). Ähnliche dreidimensionale Dosisverteilungen werden ebenfalls genutzt innerhalb der DCOG LATER Studie von Meningeomen bei Überlebenden von Kinderkrebs (Kok et al. 2019). Innerhlab dieses Projekts arbeiten wir zusammen mit Dr. Nicola Russell und Professor Floor van Leeuwen vom Netherlands Cancer Institute in Amsterdam (Niederlande), Dr. Cécile Ronckers und Professor Leontien Kremer vom DCOG LATER Konsortium des Princess Maxima Center for Pediatric Oncology in Utrecht (Niederlande), Dr. Ruth Pfeiffer vom U.S. National Cancer Institute in Bethesda (USA) und anderen internationalen Partnern.


Design und statistische Analyse klinischer Studien zur Evaluation von Markern für die personalisierte Medizin

Um die Krebsbehandlung zu verbessern werden dringend Biomarker gebraucht, die angeben, welcher Patient von welcher Behandlung profitiert – die Personalisierung der Behandlung. In der Onkologie wurden momentan nur wenige solcher Marker eingesetzt, möglicherweise weil vielversprechende Marker-Kandidaten den strengen Prozess der klinischen Entwicklung nicht überstehen. Am Beginn dieser Entwicklung stehen oft kleine nicht-randomisierte Studien. Bei undeutlichen Ergebnissen werden grössere randomisierte Studien zur Bestätigung, die für eine klinische Nutzung notwendig ist, dann nicht durchgeführt. In einem, durch die Dutch Cancer Society unterstützten, Projekt beschreiben und entwickeln ein Doktorand und Dr. Viet Nguyen statistische Designs und Methoden zur Evaluation prädiktiver Marker in nicht-randomisierten Studien oder randomisierten Studien mit archivierten Gewebeproben. Bei den Designs handelt es sich um sogenannte “case-only” und hybride Ansätze innerhalb additiver und multiplikativer Modelle. Wir untersuchen den nötigen Stichprobenumfang und die erreichte statistische Power sowie andere Eigenschaften mittels generierter Daten sowie in der Anwendung mit Daten über Marker, die ein DNA-Reparatur-Defizit messen, und Chemotherapie gegen Brustkrebs. Mehrere Studien, zum Beispiel  Vollebergh et al (2011), Schouten et al (2015) und Puppe et al (2019), suggerieren, dass ein Marker für die Reparaturkapazität von DNA-Doppelstrangbrüchen (“BRCA-like”) Frauen identifizieren kann, die deutlich von Chemotherapie mit hoher Dosis profitieren, sodass die starken Nebenwirkungen akzeptabel sind. In anderen laufenden Studien prüfen wir, ob der Marker auch Gruppen von Frauen identifizieren kann, die besonders stark auf andere Chemotherapeutika ansprechen, zum Beispiel der deutsche RCT ADAPT-TN und der Finnische FinXX RCT. Innerhalb dieses Projekts arbeiten wir zusammen mit Professor Sabine Linn vom Netherlands Cancer Institute in Amsterdam (Niederlande), Professor Rita Schmutzler von der Universität Köln, Professor Heikki Joensuu von der Universität Helsinki (Finnland) und anderen internationalen Partnern.


Krebsrisiko nach medizinischer Strahlenexposition

Diagnostische und therapeutische Verfahren sind die Hauptquelle für die Exposition der Bevölkerung mit ionisierender Strahlung, und diese werden in der Zukunft stark zunehmen. Diagnostische Computertomographie-Scans (CT) haben in der westlichen Welt in den letzten 20-30 Jahren enorm zugenommen. Auch bei Kindern wird dieser Trend beobachtet, zum Beispiel in den Niederlanden (Meulepas et al 2017). Gleichzeitig bedeutet ein CT oft eine relativ hohe Strahlenexposition des Patienten verglichen mit einer Röntgenaufnahme. Über das Krebsrisiko nach solchen Expositionen besteht Unsicherheit. Mit Unterstützung der Europäischen Kommission und Worldwide Cancer Research untersuchen wir das Krebsrisiko nach Strahlenexposition durch CT-Scans in einer grossen retrospektiven Kohorte von niederländischen Kindern (Meulepas et al 2014). Wir fanden eine Dosis-Wirkungs-Beziehung für Gehirntumore (Meulepas et al 2019). Für die “Epidemiological study to quantify risks for pediatric computerized tomography and to optimize doses” (EPI-CT), finanziert durch die Europäische Kommission, werden unsere niederländischen Daten kombiniert mit ähnlichen Daten aus 8 weiteren Europäischen Ländern. Details des Designs der kombinierten Kohorte mit etwa einer Million Kindern wurden vor Kurzem publiziert (Bernier et al 2019). 

Wir nehmen Teil an der Studie „Implications of medical low dose radiation exposure“ (MEDIRAD), finanziert durch die Europäische Kommission. Innerhalb dieses Konsortiums werden verschieden Studien zu gesundheitlichen Folgen medizinischer Strahlenexposition durchgeführt. Wir aktualisieren die im Rahmen EPI-CT Studie zusammengestellte Kohorte, um die Anzahl der Krebsfälle und damit die statistische Aussagekraft zu erhöhen. 


Indirekte Korrektur für nicht gemessene Confounder in verschiedenen Studiendesigns

Die Stärke der aus Beobachtungsstudien abgeleiteten Evidenz wird seit vielen Jahren diskutiert (Vandenbroucke 2004, Vandenbroucke 2011 ). Die Diskussion dauert bis heute an: Veröffentlichungen wie etwa die der Agency for Healthcare Research and Quality über Beurteilung und Bias-Korrektur bei Beobachtungsstudien sowie der European Medicines Agency (EMA) über die Nutzung von Patientenregistern für die Arzneimittelzulassung werden unterschiedlich bewertet. Ein Beispiel dafür sind die Stellungnahmen des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Andererseits hat Cochrane Schätzungen aus Beobachtungs- und randomisierten Studien verglichen und nur geringe Unterschiede gefunden. In der Folge gewinnt die quantitative Fehleranalyse von Beobachtungsstudien an Bedeutung. Die Anwendung entsprechender statistischer Methoden wird gefördert durch Lehrbücher wie Lash et al 2009 und Fachartikel  von Ding und VanderWeele 2016 oder VanderWeele und Ding 2017.

Bei nicht-randomisierten Studien mit medizinischen Interventionen als mögliche Ursache für Erkrankungen sind Indikationsbias eine besondere Herausforderung. Da Details der Indikationsstellung oft nicht erhoben werden können und randomisierte Studien oft nicht möglich sind, gewinnt die Beurteilung und Korrektur von Indikationsbias an Bedeutung. 

Wir haben Methoden erweitert für die Korrektur von nicht gemessenen Confoundern, zum Beispiel Indikation, in Kohorten und Fall-Kontroll-Studien zur Assoziation zwischen medizinischer Strahlenexposition und Krebsrisiko (Lubin et al 2018Meulepas et al 2016 und Meulepas et al 2017 . Wir erweitern diese Methoden auf andere Studiendesigns.


Internationale Strahlenschutzkommission (ICRP)

Als Mitglied der International Commission on Radiological Protection (ICRP), ist Michael Hauptmann beteiligt an einer Studie über Faktoren, die die individuelle Reaktion des menschlichen Organismus auf ionisierende Strahlen regulieren. Viele solcher Faktoren sind bereits bekannt (Rajaraman et al 2018) und umfassen Dosis, Dosisrate, bestrahltes Gewebevolumen, Strahlenart, Alter, Geschlecht, Lebensstil (z. B. Rauchen, Ernährung, und möglicherweise Body Mass Index), Umweltfaktoren, Genetik und Epigenetik, stochastische Verteilung zellulärer Ereignisse und andere Erkrankungen wie Diabetes or Virusinfektionen. Genetische Faktoren werden als wichtige Faktoren zur individuellen Reaktion gesehen. Diese Studie fasst die aktuelle Evidenz zusammen über Faktoren, die das Ausmaß akuter Nebenwirkungen sowie späten Gewebereaktionen nach Strahlenexposition beeinflussen.

Publikationen

Bernier MO, Baysson H, Pearce MS, Moissonnier M, Cardis E, Hauptmann M, Struelens L, Dabin J, Johansen C, Journy N, Laurier D, Blettner M, Le Cornet L, Pokora R, Gradowska P, Meulepas JM, Kjaerheim K, Istad T, Olerud H, Sovik A, Bosch de Basea M, Thierry-Chef I, Kaijser M, Nordenskjold A, Berrington de Gonzalez A, Harbron RW, Kesminiene A. The EPI-CT study: a European pooled epidemiological study to quantify the potential radiation-induced risks associated to paediatric CT-scans. Int J Epidemiol. In press.

De Boer M, Van Middelkoop M, Hauptmann M, Van der Bijl N, Bosmans J, Hendriks-Brouwer N, Schop S, De Boer JP, Overbeek LI, Lobbes MB, Klazen CA, De Jong D, Rakhorst HA, Van der Hulst RR, Van Leeuwen FE. Breast implant prevalence in the Dutch female population assessed by chest radiographs. Aesthet Surg J. In press.

Kok JL, Teepen JC, Van Leeuwen FE, Tissing WJ, Neggers SJ, Van der Pal HJ, Loonen HJ, Bresters D, Versluys B, Van den Heuvel-Eibrink MM, Van Dulmen-den Broeder E, Van der Heiden-van der Loo M, Aleman B, Daniels L, Haasbeek C, Hoeben B, Janssens G, Maduro J, Oldenburger F, Van Rij C, Tersteeg R, Hauptmann M, DCOG-LATER Study Group, Kremer LC, Ronckers CM. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age. Neuro Oncol. In press.

Puppe J, Opdam M, Schouten PC, Jóźwiak K, Lips E, Severson T, Van de Ven M, Brambillasca C, Bouwman P, Van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretic L, Caldas C, Van Lohuizen M, Hauptmann M, Rhiem K, Hahnen E, Reinhardt HC, Buettner R, Mallmann P, Schoemig-Markiefka B, Schmutzler B, Linn S, Jonkers J. EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy. Clin Cancer Res. In press.

Teepen JC, Kok JL, Kremer LC, Tissing WJ, Van den Heuvel-Eibrink MM, Loonen JJ, Bresters D, Van der Pal HJ, Versluys B, Van Dulmen-den Broeder E, Nijsten T, Hauptmann M, Hollema N, Dolsma WV, Van Leeuwen FE, Ronckers CM, DCOG-LATER Study Group. Long-term risk of skin cancer among childhood cancer survivors: a DCOG-LATER cohort study. J Natl Cancer Inst. In press.

Teepen JC, Kok JL, Kremer LC, Tissing WJE, Van den Heuvel-Eibrink MM, Loonen JJ, Bresters D, Van der Pal HJ, Versluys B, Van Dulmen-den Broeder E, Nijsten T, Hauptmann M, Hollema N, Dolsma WV, Van Leeuwen FE, Ronckers CM; DCOG-LATER Study Group. Long-term risk of skin cancer among childhood cancer survivors: A DCOG-LATER Cohort Study. J Natl Cancer Inst. In press.

Van den Berg MH, Overbeek A, Lambalk CB, Kaspers GJ, Bresters MM, Van den Heuvel-Eibrink MM, Kremer LC, Loonen JJ, Van der Pal HJ, Ronckers CM, Tissing WJ, Versluys AB, Van der Heiden-Van der Loo AC, Heijboer AC, Hauptmann M, Twisk JW, Laven JS, Beerendonk CC, Van Leeuwen FE, Van Dulmen-Den Broeder E, on behalf of the DCOG LATER-VEVO study group. Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian function. Hum Reprod. In press.

Van der Willik KD, Hauptmann M, Jóźwiak K, Vinke EJ, Ruiter R, Stricker BH, Compter A, Ikram A, Schagen SB. Trajectories of cognitive performance prior to cancer diagnosis: a population-based study. J Natl Cancer Inst. In press.

Kok JL, Teepen JC, van der Pal HJ, van Leeuwen FE, Tissing WJE, Neggers SJCMM, Loonen JJ, Louwerens M, Versluys B, Van den Heuvel-Eibrink MM, Van Dulmen-den Broeder E, Jaspers MMW, Van Santen HM, Van der Heiden-van der Loo M, Janssens GO, Maduro JH, Bruggink AH, Jongmans MC, Kremer LCM, Ronckers CM; DCOG-LATER Study Group. Histologically confirmed solid benign tumors among long-term childhood cancer survivors: A DCOG LATER record linkage study. JAMA Oncology. In press.

Teepen JC, Kremer LC, Van der Heiden-van der Loo M, Tissing WJ, Van der Pal HJ, Van den Heuvel-Eibrink MM, Loonen JJ, Louwerens M, Versluys B, Van Dulmen-den Broeder E, Visser O, Maduro JH, Van Leeuwen FE, Ronckers CM; DCOG-LATER Study Group. Clinical characteristics and survival patterns of subsequent sarcoma, breast cancer, and melanoma after childhood cancer in the DCOG-LATER cohort. Cancer Causes Control. In press.

Allodji RS, Hawkins MM, Bright CJ, Fidler-Benaoudia MM, Winter DL, Alessi D, Fresneau B, Journy N, Morsellino V, Bárdi E, Bautz A, Byrne J, Feijen ELA, Teepen JC, Vu-Bezin G, Rubino C, Garwicz S, Grabow D, Gudmundsdottir T, Guha J, Hau EM, Jankovic M, Kaatsch P, Kaiser M, Linge H, Muraca M, Llanas D, Veres C, Øfstaas H, Diallo I, Mansouri I, Ronckers CM, Skinner R, Terenziani M, Wesenberg F, Wiebe T, Sacerdote C, Jakab Z, Haupt R, Lähteenmäki P, Zaletel LZ, Kuehni CE, Winther JF, Michel G, Kremer LCM, Hjorth L, Haddy N, De Vathaire F, Reulen RC. Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup. Eur J Cancer. In press.

Streefkerk N, Heins MJ, Teepen JC, Feijen EAM, Bresters D, Van Dulmen-den Broeder E, Van der Heiden-van der Loo M, Van den Heuvel-Eibrink MM, Van Leeuwen FE, Loonen JJ, Van der Pal HJH, Ronckers CM, Versluys AB, Tissing WJE, Korevaar JC, Kremer LCM; DCOG-LATER Study Group. The involvement of primary care physicians in care for childhood cancer survivors. Pediatr Blood Cancer. In press.

Vaarwerk B, Schoot RA, Maurice-Stam H, Slater O, Hartley B, Saeed P, Gajdosova E, Van den Brekel MW, Balm AJM, Hol MLF, Van Jaarsveld S, Kremer LCM, Ronckers CM, Mandeville HC, Pieters BR, Gaze MN, Davila Fajardo R, Strackee SD, Dunaway D, Smeele LE, Chisholm JC, Caron HN, Grootenhuis MA, Merks JHM. Psychosocial well-being of long-term survivors of pediatric head-neck rhabdomyosarcoma. Pediatr Blood Cancer. In press.

Teepen JC, Curtis RE, Dores GM, Berrington de Gonzalez MM, Van den Heuvel Eibrink MM, Kremer LCM, Gilbert ES, Van Leeuwen FE, Ronckers CM, Morton LM. Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000-2011. Leukemia. In press.

Grabow D, Kaiser M, Hjorth L, Byrne J, Ronckers CM, Kaatsch P. on behalf of the PanCareSurFup Consortium The PanCareSurFup cohort of 83,333 5-year survivors of childhood cancer - Methodology and results of harmonising data to establish a cohort from 12 European countries. Eur J Epidemiol. In press.

Virgolin M, Van Dijk IWM, Wiersma J, Ronckers CM, Witteveen C, Bel A, Alderliesten T, Bosman P. On the feasibility of automatically selecting similar patients in highly individualized radiotherapy dose reconstruction for historic data of paediatric cancer survivors. Med Phys. In press.

Groot HJ, Van Leeuwen FE, Lubberts S, Horenblas S, De Wit R, Alfred Witjes J, Groenewegen G, Poortmans PM, Hulshof MCCM, Meijer OWM, De Jong IJ, Van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, Jóźwiak K, Van den Belt-Dusebout AW, Gietema JA, Schaapveld M. "Platinum exposure and cause-specific mortality among testicular cancer patients." Cancer. In press

Kho E, De Boer LL, Post AL, Van de Vijver KK, Jóźwiak K, Sterenborg HJCM, Ruers TJM. "Imaging depth variations in hyperspectral imaging: development of a method to detect tumor up to the required tumor-free margin width." J Biophotonics. In press

Min LA, Vogel WV, Lahaye MJ, Maas M, Donswijk M, Vegt E, Kusters M, Zijlmans HJ, Jóźwiak K, Roberti S, Beets-Tan RGH, Lambregts DMJ. "Integrated versus separate reading of [18F]FDG-PET/CT and MRI for abdominal malignancies effect on staging outcomes and diagnostic confidence." Eur Radiol. In press

Jacobse JN, Duane FK, Boekel NB, Schaapveld M, Hooning MJ, Seynaeve CM, Baaijens MH, Hauptmann M, Gietema JA, Aleman BM, Taylor BM, Darby BM, Van Leeuwen FE. Radiation dose-response for risk of myocardial infarction in breast cancer survivors. Int J Radiat Oncol Biol Phys 2019; 103(3): 595–604.

Kok JL, Teepen JC, Van Leeuwen FE, Tissing WJE, Neggers SJCMM, Van der Pal HJ, Loonen JJ, Bresters D, Versluys B, Van den Heuvel-Eibrink MM, Van Dulmen-den Broeder E, Van der Heiden-van der Loo M, Aleman BMP, Daniels LA, Haasbeek CJA, Hoeben B, Janssens GO, Maduro JH, Oldenburger F, Van Rij C, Tersteeg RJHA, Hauptmann M; DCOG-LATER Study Group, Kremer LCM, Ronckers CM. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age. Neuro Oncol 2019; 21(3): 392–403.

Meulepas JM, Ronckers CM, Smets AM, Nievelstein RA, Gradowska P, Lee C, Jahnen A, Van Straten M, De Wit MC, Zonnenberg B, Klein WM, Merks JH, Visser O, Van Leeuwen FE, Hauptmann M. Radiation exposure from pediatric CT scans and subsequent cancer risk in the Netherlands. J Natl Cancer Inst 2019; 111(3): 256–263.

Opstal-Van Winden AW, De Haan HG, Hauptmann M, Schmidt MK, Broeks A, Russell NS, Janus CP, Krol AD, Van der Baan FH, De Bruin ML, Van Eggermond AM, Dennis J, Culver HA, Haiman CA, Sawyer EJ, Cox A, Devilee P, Hooning MJ, Peto J, Couch FJ, Pharoah P, Orr P, Easton DF, Aleman BM, Strong LC, Bhatia S, Cooke R, Robison LL, Swerdlow AJ, Van Leeuwen FE. Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma. Blood 2019; 133(10): 1130–1139.

Puppe J, Opdam M, Schouten PC, Jóźwiak K, Lips E, Severson T, Van de Ven M, Brambillasca C, Bouwman P, van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretić L, Caldas C, van Lohuizen M, Hauptmann M, Rhiem K, Hahnen E, Reinhardt HC, Büttner R, Mallmann P, Schömig-Markiefka B, Schmutzler R, Linn S, Jonkers J. EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy. Clin Cancer Res 2019; 25(14): 4351–4362.

Spaan M, Van den Belt-Dusebout AW, Van den Heuvel-Eibrink MM, Hauptmann M, Lambalk CB, Burger CW, Van Leeuwen FE, on behalf of the OMEGA-steering group. Risk of cancer in children and young adults conceived by assisted reproductive technology. Hum Reprod 2019; 34(4): 740–750.

Elbers JBW, Veldhuis LI, Bhairosing PA, Smeele LE, Jóźwiak K, Van den Brekel MWM, Verheij M, AlMamgani A, Zuur CL. "Salvage surgery for advanced stage head and neck squa-mous cell carcinoma following radiotherapy or chemoradiation." Eur Arch Otorhinolaryngol, 2019; 276: pp. 647-655.

Berger DMS, Wassenberg RM, Jóźwiak K, Van de Wiel BA, Balm AJM, Van den Berg JG, Klop WMC. "Inter-observer variation in the histopathology reports of head and neck melanoma; a comparison between the seventh and eighth edition of the AJCC staging system." Eur J Surg Oncol, 2019; 45(2): pp. 235-241.

Elbers JBW, Al-Mamgani A, Van den Brekel MWM, Jóźwiak K, De Boer JP, Lohuis PJFM, Willems SM, Verheij M, Zuur CL. "Salvage surgery for recurrence after radiotherapy for squa-mous cell carcinoma of the head and neck". Otolaryngol Head Neck Surg, 2019; 160(6): pp. 1023-1033.

Van Eden WJ, Kok NFM, Snaebjornsson P, Jóźwiak K, Woensdregt K, Bottenberg P, Boot H, Aalbers AGJ. "Factors inuencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms." BJS Open, 2019; 3: pp. 376-386.

Wang Z, Balgobind BV, Virgolin M, Van Dijk IWEM, Wiersma J, Ronckers CM, Bosman PAN, Bel A, Alderliesten T. How do patient characteristics and anatomical features correlate to accuracy of organ dose reconstruction for Wilms' tumor radiation treatment plans when using a surrogate patient's CT scan? J Radiol Prot 2019; 39(2): 598-619.

Feijen EAML, Font-Gonzalez A, Van der Pal HJH, Kok WEM, Geskus RB, Ronckers CM, Bresters D, Van Dalen EC, Van Dulmen-den Broeder E, Van den Berg MH, Van der Heiden-Van der Loo M, Van den Heuvel-Eibrink MM, Van Leeuwen FE, Loonen JJ, Neggers SJCMM, Versluys ABB, Tissing WJE, Kremer LCM; DCOG-LATER Study Group.Risk and Temporal Changes of Heart Failure Among 5-Year Childhood Cancer Survivors: a DCOG-LATER Study. J Am Heart Assoc 2019; 8(1): e009122.

Feijen EAM, Font-Gonzalez A, Van der Pal HJH, Kok WEM, Geskus RB, Ronckers CM, Bresters D, Van Dalen EC, Van Dulmen-den Broeder E, Van den Berg MH, Van der Heiden-van der Loo M, Van den Heuvel-Eibrink MM, Van Leeuwen FE, Loonen JJ, Neggers SJCMM, Versluys AB, Tissing WJE, Kremer LCM, on behalf of the DCOG LATER Study Group. Risk and temporal changes of heart failure among 5-year childhood cancer survivors: a DCOG-LATER study. J Am Heart Assoc 2019; 8(1): e009122.

Van de Loo LEXM, Van den Berg MH, Overbeek A, Van Dijk M, Damen L, Lambalk CB, Ronckers CM, Van den Heuvel-Eibrink MM, Kremer LCM, Van der Pal HJ, Laven JSE, Tissing WJE, Loonen JJ, Versluys B, Bresters D, Kaspers GJL, Van Leeuwen FE, Van Dulmenden Broeder E; DCOG LATER-VEVO Study Group. Uterine function, pregnancy complications, and pregnancy outcomes among female childhood cancer survivors. Fertil Steril 2019; 111(2): 372-380.

Akdeniz D, Schmidt MK, Seynaeve CM, McCool D, Giardiello D, Van den Broek AJ, Hauptmann M, Steyerberg EW, Hooning MJ. Risk factors for metachronous contralateral breast cancer: a systematic review and meta-analysis. Breast 2018; 44: 1–14.

Boekel NB, Jacobse JN, Schaapveld M, Hooning MJ, Gietema JA, Duane FK, Taylor CW, Darby SC, Hauptmann M, Seynaeve CM, Baaijens MH, Sonke GS, Rutgers EJ, Russell NS, Aleman BM, Van Leeuwen FE. Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. Br J Cancer 2018; 119: 408–418.

Dackus GM, Jóźwiak K, Sonke GS, Van der Wall E, Van Diest PJ, Hauptmann M, Siesling S, Linn SC. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: a population-based cohort study. Eur J Cancer 2018; 90: 92–101.

De Boer M, Van Leeuwen FE, Hauptmann M, Overbeek LI, De Boer JP, Hijmering NJ, Sernee A, Klazen CA, Lobbes MB, Van der Hulst RR, Rakhorst HA, De Jong D. Breast implants and the risk of anaplastic large cell lymphoma in the breast. JAMA Oncol 2018; 4(3): 335–341.

Halldorsson MO, Hauptmann M, Snabjornsson P, Haraldsdottir KH, Eiriksdottir G, Aspelund T, Guamundsson EF, Guanason V, Jonasson JG, Haraldsdottir S. The risk of developing a mismatch repair deficient colorectal cancer after undergoing cholecystectomy. Scand J Gastroenterol 2018; 53(8): 972–975.

Krul IM, Opstal-Van Winden AW, Zijlstra AW, Appelman Y, Schagen SB, Meijboom L, Serne E, Lambalk CB, Lips CB, Van Dulmen-den Broeder E, Hauptmann M, Daniels LA, Aleman BM, Van Leeuwen FE. Rationale and design of a cohort study on primary ovarian insufficiency in female survivors of Hodgkin lymphoma: influence on long-term adverse effects (SOPHIA). BMJ Open 2018; 8(9): e018120.

Lubin JH, Hauptmann M, Blair A. Indirect adjustment of an exposure with multiple categories for an unmeasured confounder. Ann Epidemiol 2018; 28(11): 801–807.

Meulepas JM, Hauptmann M, Lubin JH, Shuryak I, Brenner DJ. Is there unmeasured indication bias in radiation-related cancer risk estimates from studies of computed tomography? Radiat Res 2018; 189(2): 128–135.

Rajaraman P, Hauptmann M, Bouffler S, Wojcik A. Human individual radiation sensitivity and prospects for prediction. Ann ICRP 2018; 47(3-4): 126–141.

Teepen JC, Kok JL, Van Leeuwen FE, Tissing WJE, Dolsma WV, Van der Pal HJ, Loonen JJ, Bresters D, Versluys B, Van den Heuvel-Eibrink MM, Van Dulmen-den Broeder E, Van den Berg MH, Van der Heiden-van der Loo M, Hauptmann M, Jongmans MC, Overbeek LI, Van de Vijver MJ, Kremer LCM, Ronckers CM; DCOG-LATER Study Group. Colorectal adenomas and cancers after childhood cancer treatment: A DCOG-LATER Record Linkage Study. J Natl Cancer Inst 2018; 110(7): 758–767.

Van der Willik KD, Koppelmans V, Hauptmann M, Compter A, Ikram MA, Schagen SB. Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study. Breast Cancer Res 2018; 20(1): 135.

Van der Willik K, Ruiter R, Wolters FJ, Ikram MK, Stricker BH, Hauptmann M, Compter A, Schagen SB, Ikram MA. Mild cognitive impairment and dementia show contrasting associations with risk of cancer. Neuroepidemiology 2018; 50(3–4): 207–215.

Van Gils T, Nijeboer P, Overbeek LI, Hauptmann M, Castelijn DA, Bouma G, Mulder CJ, Van Leeuwen FE, De Jong D. Risks for lymphoma and gastrointestinal carcinoma in patients with newly diagnosed adult-onset celiac disease: consequences for follow-up. United European Gastroenterol J 2018; 6(10): 1485–1495.

Van Griethuysen JJ, Bus EM, Hauptmann M, Lahaye MJ, Maas M, Ter Beek L, Beets GL, Bakers FC, Beets-Tan RG, Lambregts DM. Gas-induced susceptibility artifacts on diffusion-weighted MRI of the rectum – effect of applying a micro-enema to improve image quality. Eur J Radiol 2018; 99: 131–137.

Wojcik A, Bouffler S, Hauptmann M, Rajaraman P. Considerations on the use of the terms radiosensitivity and radiosusceptibility. J Radiol Prot 2018; 38(3): N25–N29.

Madu MF, Franke V, Van de Wiel BA, Klop WMC, Jóźwiak K, Van Houdt WJ, Wouters MWJM, Van Akkooi ACJ. "External validation of the 8th edition melanoma staging system of the American Joint Committee on Cancer (AJCC): Effect of adding EORTC sentinel node (SN) tumor burden criteria on prognostic accuracy in stage III." J Clin Oncol, 2018; 36(15 suppl): 9500-9500.

Kuusk T, De Bruijn R, Brouwer OR, De Jong J, Donswijk M, Hendricksena K, Horenblas S, Jóźwiak K, Prevoo W, Valds Olmos RA, Van Der Poel HG, Van Rhijn BWG, Wit EM, Bex A. "Outcome of sentinel lymph node biopsy in patients with clinically non-metastatic renal cell carcinoma." Scan J of Urology, 2018; 52(5-6): pp. 411-418.

Krul IMK, Opstal-Van Winden AWJ, Janus CPM, Daniels LA, Appelman Y, Maas AHEM, De Vries S, Jóźwiak K, Aleman BMP, Van Leeuwen F. "Cardiovascular disease risk after treatment-induced premature ovarian insufficiency in female survivors of Hodgkin lymphoma." J Am Coll Cardiol, 2018; 72(25): pp. 3374-3375.

Kuusk T, Donswijk ML, Valdes Olmos RA, De Bruijn RE, Brouwer OR, Hendricksen K, Horenblas S, Jóźwiak K, Prevoo W, Van Der Poel HG, Van Rhijn BWG, Wit EM, Bex A. "An analysis of SPECT/CT non-visualization of sentinel lymph nodes in renal tumors." Eur J Nucl Med Mol Imaging, 2018; 8: 105.

Groot HJ, Gietema JA, Aleman BMP, Incrocci L, De Wit R, Witjes AJ, Groenewegen G, De Brouwer P, Meijer OWM, Hulshof MCCM, Van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, Van den Bergh ACM, Kerst JM, Van den Belt-Dusebout AW, Lubberts S, Jóźwiak K, Horenblas S, Van Leeuwen FE, Schaapveld M. "Risk of diabetes after para-aortic radiation for testicular cancer". Br J Cancer, 2018; 119: pp. 901-907.

Ottenhof SR, Djajadiningrat RS, Thygesen HH, Jakobs PJ, Jóźwiak K, Heeren AM, De Jong J, Sanders J, Horenblas S, Jordanova ES. "The prognostic value of immune factors in the tumor microenvironment of penile squamous cell carcinoma." Frontiers in Immunology, 2018; 9: 1253.

Groot HJ, Lubberts S, De Wit R, Witjes JA, Kerst JM, De Jong IJ, Groenewegen G, Van den Eertwegh AJM, Poortmans PM, Klumpen H, Van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJB, Incrocci L, Van den Bergh ACM, Jóźwiak K, Van den Belt-Dusebout AW, Horenblas S, Gietema JA, Van Leeuwen FE, Schaapveld M. "Risk of solid cancer after treatment for testicular germ cell cancer in the platinum era." J Clin Oncol, 2018; 36(4): pp. 2504-2513.

Brouwer de Koning SG, Vranken Peeters MTFD, Jóźwiak K, Bhairosing P, Ruers TJM. "Tumor resection margin definitions in breast-conserving surgery: Systematic review and meta- analysis of the current literature". Clin Breast Cancer, 2018; 18(4): e595-e600.

Volders JH, Negenborn VL, Haloua MH, Krekel NMA, Jóźwiak K, Meijer S, Van den Tol MP. "Breast-specific factors determine cosmetic outcome and patient satisfaction after breast- conserving therapy: Results from the randomized COBALT study." J Surg Oncol, 2018; 117: pp. 1001-1008.

De Vries S, Schaapveld M, Van Nimwegen FA, Jóźwiak K, Lugtenburg PJ, Daniels LA, Roesink JM, Van der Maazen RWM, Kok WEM, Aleman BMP, Van Leeuwen FE. "High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors." Br J Cancer, 2018; 118: pp. 887-895.

Haupt R, Essiaf S, Dellacasa C, Ronckers CM, Schrappe M, Hjorth L, Ladenstein R. PancareSurFup, ENCAA, ExPo-r-net Working Groups. The ‘Survivorship Passport’ for Childhood Cancer Survivors. Eur J Cancer 2018; 102: 69-81.

Bright CJ, Hawkins MM, Winter DL, Alessi D, Allodji RS, Bagnasco F, Bárdi E, Bautz A, Byrne J, Feijen EAM, Fidler MM, Garwicz S, Grabow D, Gudmundsdottir T, Guha J, Haddy N, Jankovic M, Kaatsch P, Kaiser M, Kuehni CE, Linge H, Øfstaas H, Ronckers CM, Skinner R, Teepen JC, Terenziani M, Vu-Bezin G, Wesenberg F, Wiebe T, Sacerdote C, Jakab Z, Haupt R, Lähteenmäki P, Zaletel LZ, Kuonen R, Winther JF, De Vathaire F, Kremer LC, Hjorth L, Reulen RC; PanCareSurFup Consortium. Risk of soft-tissue sarcoma among 69,460 5-year survivors of childhood cancer in Europe. J Natl Cancer Inst 2018; 110(6): 649-660.

Wang Z, Van Dijk I, Wiersma J, Ronckers CM, Oldenburger F, Balgobind B, Bosman P, Bel A, Alderliesten T. Are age- and gendermatched childhood cancer patients' CT scans suitable for 2D-to-3D dose reconstruction. Med Phys 2018; 45(6): 2628-2638.

Chow EJ, Chen Y, Hudson MM, Feijen EAM, Kremer LC, Ronckers CM, Robison LL, Armstrong GT, Yasui Y. Prediction of ischemic heart disease and stroke among childhood cancer survivors. J Clin Oncol 2018; 36(1): 44-52.

Fidler MM, Reulen RC, Winter DL, Allodji RS, Bagnasco F, Bárdi E, Bautz A, Bright CJ, Byrne J, Feijen EAM, Garwicz S, Grabow D, Gudmundsdottir T, Guha J, Haddy N, Jankovic M, Kaatsch P, Kaiser M, Kuonen R, Linge H, Maule M, Merletti F, Øfstaas H, Ronckers CM, Skinner R, Teepen J, Terenziani M, Vu-Bezin G, Wesenberg F, Wiebe T, Jakab Z, Haupt R, Lähteenmäki P, Zaletel LZ, Kuehni CE, Winther JF, De Vathaire F, Kremer LC, Hjorth L, Hawkins MM. Risk of subsequent primary bone cancers among 69,460 5-year survivors of childhood and adolescent cancer diagnosed throughout Europe. J Natl Cancer Inst 2018; 110(2).

Dackus GM, Ter Hoeve ND, Opdam M, Vreuls W, Varga Z, Koop EA, Willems SM, Van Deurzen CH, Groen EJ, Cordoba-Iturriagagoitia A, Bart J, Mooyaart AL, Van den Tweel JG, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Amant F, Broeks A, Kerkhoven R, Stathonikos N, Veta M, Jóźwiak K, Hauptmann M, Hoogstraat M, Wessels LF, Schmidt MK, Sonke GS, Van der Wall E, Siesling S, Van Diest PJ, Linn SC. Long-term prognosis of adjuvant treatment naive young breast cancers patients (≤40 years): the PARADIGM initiative. BMJ Open 2017; 7(11): e017842.

Gilbert E, Curtis RE, Hauptmann M, Kleinerman RA, Lynch CF, Stovall M, Smith SA, Weathers R, Andersson M, Dores GM, Fraumeni Jr JF, Fossa SD, Hall P, Hodgson DC, Holowaty EJ, Joensuu H, Johannesen TB, Langmark F, Kaijser M, Pukkala E, Rajaraman E, Storm HH, Vaalavirta L, Van den Belt-Dusebout AW, Aleman BM, Travis LB, Morton LM, Van Leeuwen FE. Stomach cancer following Hodgkin lymphoma, testicular cancer, and cervical cancer: A pooled analysis of three international studies with a focus on radiation effects. Radiat Res 2017; 187(2): 186–195.

Krul IM, Opstal–Van Winden AW, Aleman BM, Janus CP, Van Eggermond AM, De Bruin ML, Hauptmann M, Krol AD, Schaapveld M, Broeks A, Kooijman KR, Fase S, Lybeert ML, Zijlstra JM, Van der Maazen RW, Kesminiene A, Diallo I, De Vathaire F, Russell NS, Van Leeuwen FE. Breast cancer risk after radiotherapy for Hodgkin lymphoma: influence of gonadal hormone exposure. Int J Radiat Oncol Biol Phys 2017; 99(4): 843–853.

Meulepas JM, Smets AMJB, Nievelstein RAJ, Gradowska P, Verbeke J, Holscher HC, Rutten MJCM, Kieft M, Ronckers CM, Hauptmann M. Trends and patterns of computed tomography scan use among children in the Netherlands: 1990-2012. Eur Radiol 2017; 27(6): 2426–2433.

Russell NS, Van Eggermond A, Aleman A, Krul I, Cooke R, Kuiper S, Allen SD, Wallis MG, Diallo I, De Vathaire F, Hauptmann M, Swerdlow AJ, Van Leeuwen FE. Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy. Clin Transl Rad Oncol 2017; 7: 20–27.

Teepen JC, Van Leeuwen FE, Tissing WJ, Van Dulmen-den Broeder E, Van den Heuvel-Eibrink MM, Van der Pal HJ, Loonen JJ, Bresters D, Versluys B, Neggers SJCMM, Jaspers MWM, Hauptmann M, Van der Heiden-van der Loo M, Visser O, Kremer LCM, Ronckers CM; DCOG LATER Study Group. Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER Study Cohort:  Role of chemotherapy. J Clin Oncol 2017; 35(20): 2288–2298.

Van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, Hauptmann M, Lugtenburg PJ, Janus CPM, Daniels L, Van Leeuwen FE, Cutter DJ, Aleman BMP. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood 2017; 129(16): 2257–2265.

Elbers JBW, Al-Mamgani A, Paping D, Van den Brekel MWM, Jóźwiak K, De Boer JP, Karakullukcu B, Verheij M, Zuur CL. "Definitive (chemo)radiotherapy is a curative alternative for standard of care in advanced stage squamous cell carcinoma of the oral cavity." Oral Oncol, 2017; 75: pp. 163-168.

Madu MF, Franke V, Bruin MM, Berger DMS, Bierman C, Jóźwiak K, Klop WMC, Wouters MWJM, Akkooi ACJ, Van de Wiel BA. "Immediate completion lymph node dissection in stage IIIA melanoma does not provide significant additional staging information beyond EORTC SN tumor burden criteria." Eur J Cancer, 2017; 87: pp. 212-215.

Kadouch DJ, Elshot YS, Zupan-Kajcovski B, Van Haersma de With ASE, Van der Wal AC, Leeang M, Jóźwiak K, Wolkerstorfer A, Bekkenk MW, Spuls PI, De Rie MA. "One-stop- shop with confocal microscopy imaging versus standard of care surgical treatment of basal cell carcinoma: an open label, non-inferiority, randomized controlled multicenter trial." Br J Dermatol, 2017; 177: pp. 735-741.

Madu MF, Schopman JHH, Berger DMS, Klop WMC, Jóźwiak K, Wouters MWJM, Van der Hage JA, Van Akkooi ACJ. "Clinical prognostic markers in stage IIIC melanoma." J Surg Oncol, 2017; 116: pp. 244-251.

Volders JH, Negenborn VL, Haloua MH, Krekel NMA, Jóźwiak K, Meijer S, Van den Tol MP. "Cosmetic outcome and quality of life are inextricably linked in breast conserving therapy." J Surg Oncol, 2017; 115: pp. 941-948.

Rigter LS, Spaander MCW, Moons LM, Bisseling TM, Aleman BMP, De Boer JP, Lugtenburg PJ, Janus CPM, Petersen EJ, Roesink JM, Raemaekers JMM, Van der Maazen RWM, Cats A, Bleiker EMA, Snaebjornsson P, Carvalho B, Lansdorp-Vogelaar I, Jóźwiak K, Te Riele H, Meijer GA, Van Leeuwen FE, Van Leerdam ME. "Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design." BMC Cancer, 2017; 17(1), pp. 112.

Madu MF, Deken MM, Van der Hage JA, Jóźwiak K, Wouters MWJM, Van Akkooi ACJ. "Isolated limb perfusion for melanoma is safe and effective in elderly patients." Ann Surg Oncol, 2017; 24: pp. 1997-2005.

Volders JH, Haloua MH, Krekel NMA, Negenborn VL, Kolk RHE, Lopes Cardozo AMF, Bosch AM, De Widt-Levert LM, Van der Veene H, Rijna H, Taets van Amerongen AHM, Jóźwiak K, Meijer S, va den Tol MP. "Intraoperative ultrasound guidance in breast-conserving surgery shows superiority in oncological outcome, long-term cosmetic and patient-reported outcomes: Final outcomes of a randomized controlled trial (COBALT)." EJSO, 2017; 43(4): pp. 649-657.

Van Eden WJ, Kok NFM, Jóźwiak K, Beets GL, Van Leerdam ME, Boot H, Aalbers AGJ. "Timing of systemic chemotherapy in patients with colorectal peritoneal carcinomatosis treated wit cytoreductive surgery and hyperthermic intraperitoneal chemotherapy." Dis Colon Rectum, 2017; 60(5): pp. 477-487.

Klein Hesselink M, Bocca G, Hummel Y, Brouwers A, Burgerhof J, Van Dam E, Gietema J, Havekes B, Van den Heuvel- Eibrink M, Corssmit E, Kremer L, Netea-Maier R, Van der Pal H, Peeters R, Plukker, Ronckers CM, Santen HM, Van der Meer P, Links T, Tissing W. Diastolic dysfunction is common in survivors of pediatric differentiated thyroid carcinoma. Thyroid 2017; 27: 1481-1489.

Moskowitz Ch, Chou JF, Sklar CA, Barnea D, Ronckers CM, Novetsky Friedman D, Neglia JP, Turcotte L, Howell R, Henderon TO, Armstrong GT, Leisenring WM, Robison LL, Van Leeuwen FE, Pike M, Oeffinger K. Radiation-Associated Breast Cancer and Gonadal Hormone Exposure: A Report from the Childhood Cancer Survivor Study. Br J Cancer 2017; 117: 290-299.

De Ridder M, Marres CC, Smeele LE, Van den Brekel MW, Hauptmann M, Balm AJ, Van Velthuysen ML. A critical evaluation of lymph node ratio in head and neck cancer. Virchows Arch 2016; 469(6): 635–641.

Droog M, Nevedomskaya E, Kim Y, Severson T, Flach K, Opdam M, Schuurman K, Gradowska P, Hauptmann M, Dackus G, Hollema H, Mourits M, Nederlof P, Van Boven H, Linn S, Wessels LF, Van Leeuwen FE, Zwart W. Comparative cistromics reveals genomic crosstalk between FOXA1 and ERα in tamoxifen-associated endometrial carcinomas. Cancer Res 2016; 76(13): 3773–3784.

Hauptmann M, Johannesen TB, Gilbert ES, Stovall M, Van Leeuwen FE, Rajaraman P, Smith SA, Weathers RE, Aleman BM, Andersson M, Curtis RE, Dores GM, Fraumeni Jr JF, Hall P, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Lynch CF, Pukkala E, Storm HH, Vaalavirta L, Van den Belt-Dusebout AW, Morton LM, Fossa SD, Travis LB. Increased pancreatic cancer risk following radiotherapy for testicular cancer. Br J Cancer 2016; 115: 901–908.

Kuijpers A, Hauptmann M, Aalbers A, Nienhuijs S, De Hingh I, Wiezer R, Van Ramshorst B, Van Ginkel R, Havenga K, Verwaal V. Cytoreduction and hyperthermic intraperitoneal chemotherapy: the learning curve re-assessed. Eur J Surg Oncol 2016; 42(2): 244–250.

Meulepas JM, Ronckers CM, Merks J, Weijerman ME, Lubin JH, Hauptmann M. Confounding of the association between radiation exposure from CT scans and risk of leukemia and brain tumors by cancer susceptibility syndromes. J Radiol Prot 2016; 36(4): 953–974.

Schouten PC, Vollebergh MA, Opdam M, Jonkers M, Loden M, Wesseling J, Hauptmann M, Linn SC. High expression of XIST and low expression of 53BP1 predict poor outcome after high dose alkylating chemotherapy in BRCA1-like breast cancer. Mol Cancer Therapeutics 2016; 15(1): 190–198.

Van den Belt-Dusebout AW, Spaan M, Lambalk CB, Kortman M, Laven JS, Van Santbrink EJ, Van der Westerlaken LA, Cohlen BJ, Braat DD, Smeenk JM, Land JA, Goddijn M, Van Golde RJ, Van Rumste MM, Schats R, Jóźwiak K, Hauptmann M, Rookus MA, Burger CW, Van Leeuwen FE. Association between ovarian stimulation for in vitro fertilization and long-term risk of breast cancer. JAMA 2016; 316(3): 300–312

Van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, Kooijman K, Roesink J, Van der Maazen R, Darby SC, Aleman BM, Van Leeuwen FE. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 2016; 34(3): 235–243.

De Boer LL, Hendriks BHW, Van Duijnhoven F, Vrancken Peeters-Baas M-JTFD, Van de Vijver K, Loo CE, Jóźwiak K, Sterenborg HJCM, Ruers TJM. "Using DRS during breast conserving surgery: identifying robust optical parameters and inuence of inter-patient variation." Biomed Opt Express, 2016; 7 (12): pp. 5188-5200.

Ter Brugge P, Kristel P, Van der Burg E, Boon U, De Maaker M, Lips E, Mulder L, de Ruiter J, Moutinho C, Gevensleben H, Marangoni E, Majewski I, Jóźwiak K, Kloosterman W, Van Roosmalen M, Duran K, Hogervorst F, Turner N, Esteller M, Cuppen E, Wesseling J, Jonkers J. "Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-de_cient breast cancer." J Natl Cancer Inst, 2016; 108 (11).

Madu MF, Wouters MWJM, Klop WMC, Van der Hiel B, Van de Wiel BA, Jóźwiak K, Van der Hage JA, Van Akkooi ACJ. "Clinical prognostic markers in stage III-B melanoma." Ann Surg Oncol, 2016; 23 (13): pp. 4195-4202.

Volders JH, Haloua MH, Krekel NMA, Negenborn VL, Barbe E, Sietses C, Jóźwiak K, Meijer S, Van den Tol MP. "Neoadjuvant chemotherapy in breast-conserving surgery - Consequences on margin status and excision volumes: A nationwide pathology study." Eur J Surg Oncol, 2016; 42(7): pp. 986-993.

Haloua MH, Volders JH, Krekel NMA, Barbe E, Sietses C, Jóźwiak K, Meijer S, Van den Tol MP. "A nationwide pathology study on surgical margins and excision volumes after breast- conserving surgery: There is still much to be gained." The Breast, 2016; 25: pp. 14-21.

Haloua MH, Volders JH, Krekel NMA, Lopes Cardozo AMF, De Roos WK, De Widt-Levert LM, Van der Veen H, Rijna H, Bergers E, Jóźwiak K, Meijer S, Van den Tol MP. "Intra-operative ultrasound guidance in breast-conserving surgery improves cosmetic outcomes and patient satisfaction: Results of a multicenter randomized controlled trial (COBALT)." Ann Surg Oncol, 2016; 23 (1): pp. 30-37.

Nies M, Klein Hesselink MS, Huizinga GA, Sulkers S, Brouwers AH, Burgerhof JGM, Van Dam EWCM, Havekes B, Van den Heuvel-Eibrink MM, Corssmit EPM, Kremer LCM, Netea-Maier RT, Van der Pal HJH, Peeters RP, Plukker JTM, Ronckers CM, Van Santen HM, Tissing WJE, Links TP, Bocca G. Long-term quality of life in adult survivors of pediatric differentiated thyroid carcinoma. J Clin Endocrinol Metabol 2016; 102: 1218-1226.

Klein Hesselink MS, Nies M, Bocca G, Brouwers AH, Burgerhof JG, Van Dam EW, Havekes B, Van den Heuvel-Eibrink MM, Corssmit EP, Kremer LC, Netea-Maier RT, Van der Pal HJ, Peeters RP, Schmid KW, Smit JW, Williams GR, Plukker JT, Ronckers CM, Van Santen HM, Tissing WJ, Links TP. Pediatric differentiated thyroid carcinoma in the Netherlands: a nationwide followup study. J Clin Endocrinol Metab 2016; 101: 2031-9.

Van Dijk IWEM, Van der Pal JHJ, Van Os RM, Roos YBWEM, Sieswerda E, Van Dalen EC, Ronckers CM, Oldenburger F, Van Leeuwen FE, Caron HN, Koning CCE, Kremer LCM. High risk of symptomatic stroke 25 years after radiotherapy for childhood cancer: a cohort analysis. Int J Radiat Oncol Biol Phys 2016; 96: 597-605.

Clement SC, Schoot RA, Slater O, Chisholm JC, Abela C, Balm AJM, Van den Brekel MW, Breunis WB, Chang YC, Davila Fajardo R, Dunaway D, Gajdosova E, Gaze MN, Gupta S, Hartley B, Kremer LCM, van Lennep M, Levitt GA, Mandeville HC, Pieters BR, Saeed P, Smeele LE, Strackee SD, Ronckers CM, Caron HN, Van Santen HM, Merks JHM. Endocrine disorders among survivors of childhood head and neck rhabdomyosarcoma. Eur J Cancer 2016; 54: 1-10.

Bentin Toaldo C, Alexi X, Beelen K, Kok M, Hauptmann M, Jansen M, Berns E, Neefjes J, Linn S, Michalides R, Zwart W. Protein kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13. BMC Cancer 2015; 15: 588.

Bosch de Basea M, Pearce MS, Kesminiene A, Bernier MO, Dabin J, Engels H, Hauptmann M, Krille L, Meulepas JM, Struelens L, Baatout S, Kaijser M, Maccia C, Jahnen A, Thierry-Chef I, Blettner M, Johansen C, Kjaerheim K, Nordenskjöld A, Olerud H, Salotti JA, Andersen TV, Vrijheid M, Cardis E. EPI-CT: Design, challenges and epidemiological methods of an international study on cancer risk after paediatric CT. J Radiol Prot 2015; 35(3): 611–628.

Cutter D, Schaapveld M, Darby SC, Hauptmann M, Van Nimwegen FA, Krol SA, Janus C, Van Leeuwen FE, Aleman BM. Risk of valvular heart disease after radiotherapy for Hodgkin lymphoma. J Natl Cancer Inst 2015; 107(4).

Groenendijk FH, Mellema WW, Van der Burg E, Schut E, Hauptmann M, Horlings HM, Willems SM, Van den Heuvel MM, Jonkers J, Smit EF, Bernards R. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. Int J Cancer 2015; 136(6): 1434–1444.

Hauptmann M, Fossa SD, Stovall M, Van Leeuwen FE, Johannesen TB, Rajaraman P, Gilbert ES, Smith SA, Weathers RE, Aleman BM, Andersson M, Curtis RE, Dores GM, Fraumeni Jr JF, Hall P, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Lynch CF, Pukkala E, Storm HH, Vaalavirta L, Van den Belt-Dusebout AW, Travis LB, Morton LM. Increased stomach cancer risk following radiotherapy for testicular cancer. Br J Cancer 2015; 112(1): 44–51.

Krul IM, Groeneveld E, Spaan M, Van den Belt-Dusebout AW, Mooij TM, Hauptmann M, Twisk JW, Lambers MJ, Hompes PG, Burger CW, Lambalk CB, Van Leeuwen FE on behalf of the OMEGA-project group. Increased breast cancer risk in IVF treated women with a multiple pregnancy: a new hypothesis based on old IVF treatment data. Eur J Cancer 2015; 51(1): 112–120.

Kuijpers AM, Aalbers AG, Nienhuijs SW, De Hingh IH, Wiezer MJ, Van Ramshorst B, Van Ginkel RJ, Havenga K, Heemsbergen WD, Hauptmann M, Verwaal VJ. Implementation of a standardized HIPEC protocol improves outcome for peritoneal malignancy. World J Surg 2015; 39(2): 453–460.

Pearce N, Blair A, Vineis P, Anto J, Armstrong B, Attfield M, Baccarelli A, Beane Freeman L, Beland F, Berrington A, Bertazzi P, Birmbaum L, Bucher J, Cardis E, Cherrie J, Christiani D, Cocco P, Coggon D, Comba P, Demers P, Dement J, Douwes J, Engel L, Fletcher T, Fontham E, Forastiere F, Friesen M, Fritschi L, Gerin M, Goldberg M, Grandjean P, Gustavsson P, Hartge P, Hansen J, Hauptmann M, Heederick D, Hoppin J, Huff J, Jarvholm B, Karagas M, Kjuus H, Kogevinas M, Kriebel D, Kristensen P, Kromhout H, Laden F, Lebailly P, Lemasters G, Lubin J, Lynch C, Lynge E, Mannetje A, McLaughlin J, Merchant J, Merletti F, Miller A, Parent ME, Perry M, Pesatori A, Pirastu R, Porta M, Pukkala E, Rice C, Ritz B, Ruder A, Rushton L, Rusyn I, Samet J, De Sanjose S, Saracci R, Schernhammer E, Schulte P, Sexias N, Silvermann D, Simonato L, Smith A, Spinelli J, Stayner L, Steenland K, Stenzel T, Stewart B, Stewart T, Symanski E, Terracini B, Vainio H, Vena J, Vermeulen R, Victora C, Wagner G, Ward E, Weinberg C, Weisenburger D, Whelan B, Zahm S, Zhang Y. Evidence assessment for Public Health: the 40 years work of the IARC Monographs. Environ Health Persp 2015; 123(6): 507–514.

Schouten PC, Marme F, Aulmann S, Sinn HP, Van Essen HJ, Ylstra B, Hauptmann M, Schneeweiss A, Linn SC. Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy. Clin Cancer Res 2015; 21(4): 763–770.

Theunissen EA, Zuur CL, Jóźwiak K, Lopez-Yurda M, Hauptmann M, Rasch CR, Van der Baan S, De Boer JP, Dreschler WA, Balm AJ. Prediction of hearing loss due to cisplatin chemoradiotherapy. JAMA Otolaryngol Head Neck Surg 2015; 141(9): 810–815.

Clement SC, Peeters RP, Ronckers CM, Links TP, Van den Heuvel-Eibrink MM, Nieveen van Dijkum EJ, Van Rijn RR, Van der Pal HJ, Neggers SJ, Kremer LC, van Eck-Smit BL, Van Santen HM. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma - A systematic review. Cancer Treat Rev 2015; 41: 925-34.

Schoot RA, Slater O, Ronckers CM, Zwinderman AH, Balm A, Hartley B, Van den Brekel M, Gupta S, Saeed P, Gajdosova E, Pieters BR, Gaze MN, Mandeville HC, Davila Fajardo R, Ch'ing Chang Y, Strackee SD, Dunaway D, Abela Ch, Mason C, Smeele LE, Chisholm JC, Levitt G, Kremer LC, Grootenhuis MA, Maurice-Stam H, Stiller CA, Hammond P, Caron HN, Merks JHM. Adverse events of local treatment in head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment. Eur J Cancer 2015; 51: 1424-34.

Huijskens SC, van Dijk IWEM, De Jong R, Visser J, Dávila Fajardo R, Ronckers CM, Janssens GORJ, Maduro JH, Rasch CRN, Alderliesten T, Bel A. Quantification of renal and diaphragmatic interfractional motion in pediatric image-guided radiation therapy: A multicenter study. Radiother Oncol 2015; 117: 425-31.

Theunissen EA, Zuur CL, Bosma SC, Lopez Yurda M, Hauptmann M, Van der Baan S, De Boer JP, Van der Molen L, Rasch CR, Dreschler WA, Balm AJ. Long-term hearing loss after chemoradiation in patients with head and neck cancer. Laryngoscope 2014; 124(12): 2720–2725.

Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Van de Vijver MJ, De Vries EG, Van Tinteren H, Jonkers J, Hauptmann M, Rodenhuis S, Linn SC. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res 2014; 16(3): R47.

Meulepas JM, Ronckers CM, Smets AM, Nievelstein RA, Jahnen A, Lee C, Kieft M, Lameris JS, Van Herk M, Greuter MJ, Jeukens CR, Van Straten M, Visser O, Van Leeuwen FE, Hauptmann M. Leukemia and brain tumors among children after radiation exposure from CT scans: design and methodological opportunities of the Dutch Pediatric CT Study. Eur J Epidemiol 2014; 29(4): 293–301.

Kuijpers AM, Mehta AM, Boot H, Van Leerdam ME, Hauptmann M, Aalbers AG, Verwaal VJ.  Perioperative systemic chemotherapy in peritoneal carcinomatosis of lymph node positive colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Oncol 2014; 25(4): 864–869.

Marres CC, De Ridder MD, Hegger I, Van Velthuysen ML, Hauptmann M, Navran A, Balm AJ. The influence of nodal yield in neck dissections on lymph node ratio in head and neck cancer. Oral Oncol 2014; 50(1): 59–64.

Van Dijk IWEM, Van Os RM, Van de Kamer, JB, Franken NAP, Van der Pal HJH, Koning CCE, Caron HN, Kremer LC*, Ronckers CM*. The use of equivalent radiation dose in the evaluation of late effects after childhood cancer treatment. J Cancer Surviv 2014; 8: 638-46.

Van den Berg MH, Van Dulmen-den Broeder E, Overbeek A, Ronckers CM, Van Dorp W, Kremer LC, Van den Heuvel-Eibrink MM, Huizinga GA, Loonen JJ, Versluys AB, Bresters D, Lambalk CB, Kaspers GJL, Van Leeuwen FE. Fertility studies in female childhood cancer survivors: selecting appropriate comparison groups. Reprod Biomed Online 2014; 29: 352-61.

Morton LM, Dores GM, Curtis RE, Lynch CF, Stovall M, Hall P, Gilbert ES, Aleman BM, Hodgson DC, Storm HH, Johannesen TB, Smith SA, Weathers RE, Andersson M, Fossa SD, Hauptmann M, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Pukkala E, Vaalavirta L, Van den Belt-Dusebout AW, Fraumeni Jr. JF, Travis LB, Van Leeuwen FE. Stomach cancer risk after treatment for Hodgkin lymphoma. J Clin Oncol 2013; 31(27): 3369–3377.

Stiekema J, Cats A, Kuijpers A, Van Coevorden F, Boot H, Jansen EP, Verheij M, Balague Ponz O, Hauptmann M, Van Sandick JW. Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? Eur J Surg Oncol 2013; 39(7): 686–693.

Beelen K, Opdam M, Severson T, Koornstra RH, Vincent AD, Hauptmann M, Van Schaik RH, Berns EM, Vermorken JB, Van Diest PJ, Linn SC. CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. Breast Cancer Res Treat 2013; 139(3): 649–655.

 Beane Freeman LE, Blair A, Lubin JH, Stewart PA, Hayes RB, Hoover RN, Hauptmann M. Mortality from solid tumors among workers in formaldehyde industries: an update of the NCI cohort. Am J Ind Med 2013; 56: 1015–1026.

Schouten PC, Van Dyk E, Braaf LM, Mulder L, Lips EH, De Ronde JJ, Holtman L, Wesseling J, Hauptmann M, Wessels LF, Linn SC, Nederlof PM. Platform comparisons for identification of breast cancers with a BRCA-like copy number profile. Breast Cancer Res Treat 2013; 139(2): 317–327.

Lodder WL, Lange CA, Van Velthuysen ML, Hauptmann M, Balm AJ, Van den Brekel MW, Pameijer FA. Can extranodal spread in head and neck cancer be detected on MR imaging. Oral Oncol 2013; 49(6): 626–633.

Van Monsjou HS, Lopez-Yurda M, Hauptmann M, Van den Brekel MW, Balm AJ, Wreesmann VB. Oral and oropharyngeal squamous cell carcinoma in young patients: The Netherlands Cancer Institute experience. Head Neck 2013; 35(1): 94–102.

Jóźwiak K, Moerbeek M. "Optimal designs for trials with discrete-time survival endpoints." OA Epidemiology, 2013; 1(3): 22. Invited paper.

Moerbeek M, Jóźwiak K. "Optimal designs for event history analysis." Zeitschrift für Psychologie, 2013; 221(3): pp. 160-173. Invited paper for special issue on optimal designs.

Jóźwiak K, Moerbeek M. "PODSE: A computer Program for Optimal design of trials with Discrete-time Survival Endpoints." Comput Methods Programs Biomed, 2013; 111: pp. 115- 127.

Jóźwiak K, Moerbeek M. "Optimal treatment allocation and study duration for trials with discrete-time survival endpoints." J Stat Plan Inference, 2013; 143: pp. 971-982.

Van Dijk IWEM, Cardous-Ubbink MC, Van der Pal HJH, Heinen RC, Van Leeuwen FE, Oldenburger F, Vn Os R, Ronckers CM, Schouten - van Meeteren AYN, Caron HN, Koning CCE, Kremer LCM. Dose-effect relationships for adverse events after cranial radiotherapy in long-term childhood cancer survivors. Int J Radiat Oncol Biol Phys 2013; 85: 768-775.

Kovalchik SA, Ronckers CM, Veiga LH, Sigurdson AJ, Inskip PD, De Vathaire F, Sklar CA, Donaldson SS, Anderson H, Bhatti P, Hammond S, Leisenring WM, Mertens AC, Smith SA, Stovall M, Tucker MA, Weathers RE, Robison LL, Pfeiffer RM. Absolute risk of second primary thyroid cancer for 5-year survivors of a childhood cancer. J Clin Oncol 2013; 31: 119-27.

Overbeek A, Van den Berg MH, Hukkelhoven CWPM, Kremer LC, Van den Heuvel-Eibrink MM, Tissing WJE, Loonen JJ, Versluys AB, Bresters D, Kaspers GJL, Lambalk CB, Van Leeuwen FE, Van Dulmen-den Broeder, and the DCOG LATER/VEVO Study Group. Validity of self-reported data on pregnancies: a comparison with data from a nationwide population-based registry. Hum Reprod 2013; 28:819-27.

Pijpe A, Andrieu N, Easton DF, Kesminiene A, Cardis E, GENEPSO, Nogues C, Gauthier-Villars M, Lasset C, Fricker JP, EMBRACE, Peock S, Frost D, Evans DG, Eeles RA, Paterson J, HEBON, Manders P, Van Asperen CJ, Ausems MG, Meijers-Heijboer H, Thierry-Chef I, Hauptmann M, Goldgar D, Rookus MA, Van Leeuwen FE. Diagnostic radiation exposure and breast cancer risk in BRCA1/2 mutation carriers in the GENE-RAD-RISK study. BMJ 2012; 345: e5660.

Kok M, Koornstra RH, Mook S, Hauptmann M, Fles R, Simon I, Glas A, Jansen MP, Berns EM, Foekens JA, Linn SC, Van ’t Veer LJ. Additional value of 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer. Breast 2012; 21: 769–778.

Kreeft AM, Smeele LE, Rasch CR, Hauptmann M, Rietveld DH, Leemans CR, Balm AJ. Preoperative imaging and surgical margins in maxillectomy patients. Head Neck 2012; 34(11): 1652–1656.

Ackerstaff AH, Rasch CR, Balm AJ, De Boer JP, Wiggenraad R, Rietveld DH, Gregor RT, Kroger R, Hauptmann M, Vincent A, Hilgers FJ. Five-year quality of life results of the randomized clinical phase III (RADPLAT) trial, comparing concomitant intra-arterial versus intravenous chemoradiotherapy in locally advanced head and neck cancer. Head Neck 2012; 34(7): 974–980.

Jóźwiak K, Moerbeek M. "Accrual by groups in trials with discrete-time survival endpoints." Clinical Trials, 2012; 10: pp. 32-42.

Jóźwiak K, Moerbeek M. "Cost-e_ective designs for trials with discrete-time survival end- points." Comput Stat Data Anal, 2012; 56: pp. 2086-2096.

Jóźwiak K, Moerbeek M. "Power analysis for trials with discrete-time survival endpoints." J Educ Behav Stat, 2012: 37(5): pp. 630-654.

Van den Berg MH, Overbeek A, Kremer LC, van den Heuvel-Eibrink MM, Tissing WJE, Loonen JJ, Versluys AB, Bresters D, Kaspers GJL, Lambalk CB, Van Leeuwen FE, Van Dulmen-den Broeder, and the DCOG LATER-VEVO study group. A nationwide study on reproductive function, ovarian reserve, and risk of premature menopause in female survivors of childhood cancer: design and methodological challenges. BMC Cancer 2012; 12: 363.

Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, Howe NL, Ronckers CM, Rajaraman P, Craft AW, Parker L, Berrington de Gonzalez A. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours, an historical cohort study. Lancet 2012; 380: 499-505.

Veiga LHS, Bhatti P, Ronckers CM, Sigurdson AJ, Stovall M, Smith SA, Weathers MS, Leisenring W, Mertens AC, Hammond S, Neglia JP, Meadows AT, Donaldson SS, Sklar CA, Friedman DL, Robison LL, Inskip PD. Chemotherapy and the risk of thyroid cancer after a childhood malignancy: an update from the Childhood Cancer Survivor study. Cancer Epidemiology Biomarkers Prevention 2012; 21: 92-101

Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Schmidt MK, Van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, De Vries EG, Schrama JG, Wesseling J, Van de Vijver MJ, Van Tinteren H, De Bruin M, Hauptmann M, Rodenhuis S, Linn SC. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2011; 22(7): 1561–1570.

Molloy TJ, Devriese LA, Helgason HH, Bosma AJ, Hauptmann M, Voest EE, Schellens JH, Van’t Veer LJ. A multi-marker QPCR-based platform for the detection of circulating tumor cells in patients with early-stage breast cancer. Br J Cancer 2011; 104(12): 1913–1919.

Knegjens JL, Pameijer FA, Hauptmann M, Balm AJ, Hoebers FJ, De Bois JA, Kaanders JH, Verhoef LC, Wijers OB, Wiggenraad RG, Buter J, Rasch CR. Tumor volume as outcome predictor in hemoradiation for advanced head and neck cancer. Head Neck 2011; 33(3): 375–382.

Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van ’t Veer LJ, Wessels LF, Neefjes J, Stal O, Linn SC, Landberg G, Michalides R. PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat 2011; 125: 1–12.

Vollebergh MA, Kappers I, Klomp HM, Buning-Kager JC, Korse CM, Bonfrer JM, Hauptmann M, De Visser KE, Van den Heuvel MM, Linn SC. Ligands of epidermal growth factor receptor and the insulinlike growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010; 5(12): 1939–1948.

Borst GR, Ishikawa M, Nijkamp J, Hauptmann M, Shirato H, Bengua G, Onimaru R, De Bois JA, Lebesque JV, Sonke JJ. Radiation pneumonitis after hypofractionated radiotherapy: evaluation of the LQ(L) model and different dose parameters. Int J Radiat Oncol Biol Phys 2010; 77(5): 1596–1603.

Van der Pal HJ, Van Dalen EC, Hauptmann M, Kok WE, Caron HN, Van den Bos C, Oldenburger F, Koning CC, Van Leeuwen FE, Kremer LC. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med 2010; 170(14): 1247–1255.

Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, Van de Vijver M, Koornstra RH, Buenode- Mesquita JM, Linn SC, Van ’t Veer LJ. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010; 120(3): 655–661.

De Jong MC, Pramana J, Knegjens JL, Balm AJ, Van den Brekel MW, Hauptmann M, Begg AC, Rasch CR. HPV and high risk gene expression profiles predict response to chemoradiotherapy in head and neck cancer independent of clinical factors. Radiother Oncol 2010; 95(3): 365–370.

Rasch CR, Hauptmann M, Schornagel J, Wijers O, Buter J, Gregor T, Wiggenraad R, De Boer JP, Ackerstaff AH, Kroger R, Hoebers FJ, Balm AJ. Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: results of a randomized phase III trial. Cancer 2010; 116(9): 2159–2165.

Retel VP, Joore MA, Knauer M, Linn SC, Hauptmann M, Van Harten WH. Cost-effectiveness of the 70-gene signature versus Sankt Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer 2010; 46(8): 1382–1391.

Brown LM, Gridley G, Wu AH, Falk RT, Hauptmann M, Kolonel LN, West DW, Nomura AMY, Pike MC, Hoover RN, Ziegler RG. Low level alcohol intake, cigarette smoking and risk of breast cancer in Asian-American women. Breast Cancer Res Treat 2010; 120: 203–210.

Zhang L, Tang X, Rothman N, Vermeulen R, Ji Z, Shen M, Qiu C, Guo W, Liu S, Reiss B, Beane Freeman L, Ge Y, Hubbard AE, Hua M, Blair A, Galvan N, Ruan X, Alter BP, Xin KX, Li S, Moore LE, Kim S, Xie Y, Hayes RB, Azuma M, HauptmannM, Xiong J, Stewart PA, Li L, Rappaport SM, Huang H, Fraumeni Jr. JF, Smith MT, Lan Q. Occupational exposure to formaldehyde, hematotoxicity and leukemia-specific chromosome changes in cultured myeloid progenitor cells. Cancer Epidemiol Biomarkers Prev 2010; 19: 80–88.

Kurowicka D, Nauta M, Jóźwiak K, Cooke R. "Updating parameters of the chicken processing line model." Risk Analysis, 2010; 30(6): pp. 934-944.

Bhatti P, Veiga LHS, Ronckers CM, Sigurdson AJ, Stovall M, Smith SA, Weathers MS, Leisenring W, Mertens AC, Hammond S, Friedman DL, Neglia JP, Meadows AT, Donaldson SS, Sklar CA, Robison LL, Inskip PD. Radiotherapy for childhood cancer and risk of thyroid cancer in a large cohort study: An update from the Childhood Cancer Survivor Study. Radiat Res 2010; 174: 741-52.

Ronckers CM, Land CE, Miller JS, Stovall M, Lonstein JE, Doody MM. Cancer mortality among women frequently exposed to radiographic exams for spinal disorders. Radiat Res 2010; 174: 83–90.

Kok M, Holm-Wigerup C, HauptmannM, Michalides R, Stal O, Linn S, Landberg G. Estrogen receptor- α phosphorylation at serine-118 and tamoxifen response in breast cancer. J Natl Cancer Inst 2009; 101: 1725–1729.

Hauptmann M, Stewart PA, Lubin JH, Beane Freeman LE, Hornung RW, Herrick RF, Hoover RN, Fraumeni JF Jr, Blair A, Hayes RB. Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde in the funeral industry. J Natl Cancer Inst 2009; 101: 1696–1708.

Van den Belt-Dusebout AW, Aleman BM, Besseling G, De Bruin ML, Hauptmann M, Van ’t Veer MB, De Wit R, Ribot JG, Noordijk EM, Kerst JM, Gietema JA, Van Leeuwen FE. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys 2009; 75: 1420–1429.

Borst GR, Ishikawa M, Nijkamp J, Hauptmann M, Shirato H, Onimaru R, Van den Heuvel MM, Belderbos J, Lebesque JV, Sonke JJ. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. Radiother Oncol 2009; 91: 307–313.

Beane Freeman LE, Blair A, Lubin JH, Stewart PA, Hayes RB, Hoover RN, Hauptmann M. Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries: update of the NCI cohort. J Natl Cancer Inst 2009; 101: 751–761.

Wildeman MA, Gibcus JH, Hauptmann M, Begg AC, Van Velthuysen ML, Hoebers FJ, Mastik MF, Schuuring E, Van der Wal JE, Van den Brekel MW. Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response? Laryngoscope 2009; 119: 316–322.

Holm C, Kok M, Michalides R, Fles R, Koornstra RH, Wesseling J, Hauptmann M, Neefjes J, Peterse JL, Stal O, Landberg G, Linn SC. Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol 2009; 217: 372–379.

Pietersen AM, Horlings HM, Hauptmann M, Langerod A, Ajouaou A, Cornelissen-Steijger P, Wessels LF, Jonkers J, Van de Vijver MJ, Van Lohuizen M. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 2009; 10: R109.

Kok M, Linn SC, Van Laar RK, Jansen MP, Van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van ’t Veer LJ, Berns EM. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2009; 113: 275–283.

Hooning MJ, Aleman BM, Hauptmann M, Baaijens MH, Klijn JG, Noyon R, Stovall M, Van Leeuwen FE. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol 2008; 26: 5561–5568.

Berhane K, Hauptmann M, Langholz B. Using tensor product splines in modeling exposure-timeresponse relationships: application to the Colorado Plateau uranium miners cohort. Stat Med 2008; 27: 5484–5496.

Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, De Jong D, Van de Vijver MJ, Van ’t Veer LJ, Peterse JL. Refinement of breast cancer classification by molecular haracterization of histological special types. J Pathol 2008; 216: 141–150.

Chodick G, Bekiroglu N, HauptmannM, Alexander BH, Freedman DM, Doody MM, Cheung LC, Simon SL, Weinstock RM, Bouville A, Sigurdson AJ. Risk of cataract after exposure to low doses of ionizing radiation: a 20-year prospective cohort study among US radiologic technologists. Am J Epidemiol 2008; 168: 620–631.

Sigurdson AJ, Ha M, Hauptmann M, Bhatti P, Sram R, Beskid O, Tawn EJ, Whitehouse CA, Lindholm C, Nakano M, Kodama Y, Nakamura N, Vorobstova I, Oestreicher U, Stephan G, Yong LC, Bauchinger M, Schmid E, Chung HW, Darroudi F, Roy L, Voisin P, Barquinero JF, Livingston G, Blakey D, Hayata I, Zhang W, Wang C, Bennett LM, Littlefield LG, Edwards AA, Kleinerman RA, Tucker JD. International study of factors affecting human chromosome translocations. Mutat Res 2008; 652: 112–121.

Ji BT, Blair A, Shu XO, Dosemeci M, Hauptmann M, Yang G, Chow WH, Lubin JH, Gao YT, Rothman N, Zheng W. Occupation and breast cancer risk among Shanghai women in a population-based cohort study. Am J Ind Med 2008; 51: 100–110.

De Bruin ML, Huisbrink J, Hauptmann M, Kuenen MA, Ouwens GM, Van ’t Veer MB, Aleman BM, Van Leeuwen FE. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 2008; 111: 101–108.

Bhatti P, Struewing JP, Alexander BH, Hauptmann M, Bowen L, Mateus-Pereira LH, Pineda MA, Simon SL, Weinstock RM, Rosenstein M, Stovall M, Preston DL, Linet MS, Doody MM, Sigurdson AJ. Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. radiologic technologists. Int J Cancer 2008; 122: 177–182.

Ronckers CM, Doody MM, Lonstein JE, Stovall M, Land CE. Multiple diagnostic X-rays, spine deformities and risk of breast cancer. The U.S. Scoliosis Cohort Study. Cancer Epidemiology Biomarkers Prevention 2008; 17: 605-13.

Bluhm EC, Ronckers CM, Hayashi RJ, Neglia JP, Mertens AC, Stovall M, Meadows AT, Mitby PA, Whitton JA, Hammond S, Barker JD, Donaldson SS, Robison LL, Inskip PD. Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2008; 111: 4014-21.

Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Ajouaou A, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, Van de Vijver MJ, Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of Trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395–402.

Sigurdson AJ, Bhatti P, Doody MM, Hauptmann M, Bowen L, Simon SL, Weinstock RM, Linet MS, Rosenstein M, Stovall M, Alexander BH, Preston DL, Struewing JP, Rajaraman P. Polymorphisms in apoptosis- and proliferation-related genes, ionizing radiation exposure, and risk of breast cancer among U.S. radiologic technologists. Cancer Epidemiol Biomarkers Prev 2007; 16: 2000–2007.

Lubin JH, Caporaso N, Alavanja M, Wichmann HE, Schaffrath-Rosario A, Krewski D, Zielinski JM, Brownson R, Field RW, Letourneau EG, Lynch CF, Sandler DP, Schoenberg JB, Wilcox HB, Kleinerman R, Wang Z, Hauptmann M, Langholz B, Hartge P, Garcia-Closas M, Hayes RB, Silverman DT, Brown LM. Cigarette smoking and cancer: modeling total exposure and intensity. Am J Epidemiol 2007; 166: 479–89.

Ha M, Mabuchi K, Sigurdson AJ, Freedman MD, Linet MS, Doody MM, Hauptmann M. Smoking cigarettes before first childbirth increases risk of breast cancer. Am J Epidemiol 2007; 166: 55–61.

Bhatti P, Preston DL, Doody MM, Hauptmann M, Kampa D, Alexander BH, Petibone D, Simon SL, Weinstock RM, Bouville A, Yong LC, Freedman DM, Mabuchi K, Linet MS, Edwards AA, Tucker JD, Sigurdson AJ. Retrospective biodosimetry among United States radiologic technologists. Radiat Res 2007; 167: 727–734.

Krstev S, Ji BT, Shu XO, Blair A, Zheng W, Lubin JH, Vermeulen R, Hauptmann M, Rothman N, Gao YT, Mustafa D, Chow WH. Occupation and adult-onset asthma among Chinese women in a population-based cohort. Am J Ind Med 2007; 50: 265–273.

Chodick G, Ronckers CM, Shalev V, Ron E. Excess lifetime mortality due to radiation exposure from pediatric computed tomography examinations. Isr Med Assoc J 2007; 9: 584-7.

Van den Broeck GB, Balm AJM, Van den Brekel MWM, Hauptmann M, Schornagel JH, Rasch CRN. Relationship between clinical factors and the incidence of toxicity after intra-arterial chemoradiation for head and neck cancer. Radiother Oncol 2006; 81: 143–150.

Rajaraman P, Sigurdson AJ, Doody MM, Freedman DM, Hauptmann M, Alexander BH, Linet MS. Lung cancer incidence among U.S. radiologic technologists, 1983–1998. Int J Cancer 2006; 119: 2481– 2486.

Zabel EW, Alexander BH, Mongin SJ, Doody MM, Sigurdson AJ, Linet MS, Freedman DM, Hauptmann M, Mabuchi K, Ron E. Thyroid cancer and employment as a radiologic technologist. Int J Cancer 2006; 119: 1940–1945.

Linet MS, Hauptmann M, Freedman DM, Alexander BH, Miller J, Sigurdson AJ, Doody MM. Interventional radiography and mortality risks in U.S. radiologic technologists. Pediatr Radiol 2006; 36:113–120.

Doody MM, Freedman DM, Alexander BH, Hauptmann M, Rao RS, Miller J, Mabuchi K, Ron E, Sigurdson AJ, Linet MS. Breast cancer incidence in U.S. radiologic technologists. Cancer 2006; 106: 2707–2715.

Simon SL, Weinstock RM, Doody MM, Neton J, Wenzel T, Stewart P, Mohan AK, Yoder C, Freedman M, Hauptmann M, Ron E, Bouville A, Feng A, Cardarelli J, Utterback D, Linet M. Estimating historical radiation doses to a cohort of U.S. radiologic technologists. Radiat Res 2006; 166: 174–192.

Chodik G, Ronckers CM, Ron E, Shalev V. The utilization of pediatric computed tomography in a large Israeli HMO. Pediatric Radiol 2006; 36: 485-90.

Ronckers CM, Sigurdson AJ, Stovall M, Smith SA, Mertens AC, Liu Y, Hammond S, Land CE, Neglia JP, Meadows AT, Sklar CA, Robison LL, Inskip P. Thyroid cancer following pediatric malignancies: A detailed evaluation of radiation dose-response and its modifiers. Radiat Res 2006; 166: 618-28.

Bassal M, Mertens AC, Taylor L, Neglia JP, Greffe BS, Hammond S, Ronckers CM, Friedman DL, Stovall M, Yasui Y, Meadows AT, Kadan-Lottick NS. Risk of a carcinoma as a subsequent primary neoplasm in survivors of childhood cancer: A report from the childhood cancer survivor study. J Clin Oncol 2006; 24: 476-83.

Linet MS, Freedman DM, Mohan AK, Doody MM, Ron E, Mabuchi K, Alexander BH, Sigurdson A, HauptmannM. Incidence of hematopoietic malignancies in U.S. radiologic technologists. Occup Environ Med 2005; 62: 861–867.

Sigurdson AJ, Hauptmann M, Alexander BH, Doody MM, Thomas CB, Struewing JP, Jones IM. DANN damage among thyroid cancer and multiple cancer cases, controls, and long-lived individuals. Mut Res 2005; 586: 173–188.

Cogliano VJ, Grosse Y, Baan RA, Straif K, Secretan MB, Ghissassi FE, and the Working Group for Volume 88. Summary of IARC Monographs on Formaldehyde, 2-Butoxyethanol, and 1-tert-Butoxy-2- Propanol. Environ Health Persp 2005; 113: 1205–1208.

Peters A, von Klot S, Heier M, Trentinaglia I, Cyrys J, Hörmann A, Hauptmann M, Wichmann HE, Löwel H. Particulate air pollution and nonfatal cardiac events. Part I. Air pollution, personal activities, and onset of myocardial infarction in a case-crossover study. Res Rep Health Eff Inst 2005; 124: 1–66.

Yoshinaga S, Hauptmann M, Sigurdson AJ, Doody MM, Freedman DM, Alexander BH, Linet MS, Ron E, Mabuchi K. Non-melanoma skin cancer in relation to ionizing radiation exposure among U.S. radiologic technologists. Int J Cancer 2005; 115: 828–834.

Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, Berkow R, Sklar CA, Hammond S, Neglia JP, Meadows AT, Robison LL, Inskip PD. Second primary thyroid cancer after a first childhood malignancy: A report from the Childhood Cancer Survivor Study. Lancet 2005; 365: 2014-23.

Ronckers CM, McCarron P, Ron E. Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 2005; 117: 281-88.

Zhang Y, Graubard BI, Klebanoff MA, Ronckers CM, Stanczyk FZ, Longnecker MP, McGlynn KA. Maternal hormone levels among populations at high and low risk of testicular germ cell cancer. Br J Cancer 2005; 92: 1787-93.

Hauptmann M, Lubin JH, Hayes RB, Stewart P, Blair A. Mortality from solid cancers among industrial workers exposed to formaldehyde. Am J Epidemiol 2004; 159: 1117–1130.

Sigurdson AJ, Hauptmann M, Chatterjee N, Alexander BH, Doody MM, Rutter JL, Struewing JP. Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. BMC Cancer 2004; 4:9.

Ronckers CM, Land CE, Hayes RB, Verduijn PG, van Leeuwen FE. Factors impacting questionnaire response in a Dutch retrospective cohort study. Ann Epidemiol 2004; 14: 66-72.

Travis LB, Hauptmann M, Gaul LK, Storm HH, Goldman MB, Nyberg U, Berger E, Janower ML, Hall P, Monson RR, Holm LE, Land CE, Schottenfeld D, Boice JD Jr, Andersson M. Site-specific cancer incidence and mortality after cerebral angiography with or without radioactive thorotrast. Radiat Res 2003; 160: 691–706.

Hauptmann M, Lubin JH, Hayes RB, Stewart P, Blair A. Mortality from lymphohematopoietic malignancies among workers employed in formaldehyde industries. J Natl Cancer Inst 2003; 95: 1615–1623.

Sigurdson AJ, Doody MM, Rao RS, Freedman DM, Alexander BH, Hauptmann M, Mohan AK, Yoshinaga S, Hill DA, Tarone R, Mabuchi K, Ron E, Linet MS. Cancer incidence in the U.S. radiologic technologists Health Study, 1983–1998. Cancer 2003; 97: 3080–3089.

Hauptmann M, Mohan AK, Doody MM, Linet MS, Mabuchi K. Mortality from diseases of the circulatory system in U.S. radiologic technologists. Am J Epidemiol 2003; 157: 239–248.

Freedman DM, Sigurdson AJ, Rao RS, Hauptmann M, Alexander BH, Mohan AK, Doody MM, Linet MS. Risk of melanoma among radiologic technologists in the United States. Int J Cancer 2003; 103: 556–562.

Mohan AK, Hauptmann M, Freedman DM, Ron E, Matanoski GM, Lubin JH, Alexander BH, Boice JD, Doody MM, Linet MS. Cancer and other causes of mortality among radiologic technologists in the United States. Int J Cancer 2003; 103: 259–267.

Walcott FL, Hauptmann M, Duphorne CM, Pillow PC, Strom SS, Sigurdson AJ. A case-control study of dietary phytoestrogens and testicular cancer risk. Nutr Cancer 2002; 44: 44–51.

Mohan AK, Hauptmann M, Linet MS, Ron E, Lubin JH, Freedman DM, Alexander BH, Boice JD, Doody MM, Matanoski GM. Breast cancer mortality among radiologic technologists in the United States. J Natl Cancer Inst 2002; 94: 943–948.

Hauptmann M, Pohlabeln H, Lubin JH, Jöckel KH, Ahrens W, Brüske-Hohlfeld I, Wichmann HE. The exposure-time-response-relationship between occupational asbestos exposure and lung cancer in two German case-control studies. Am J Ind Med 2002; 41: 89–97.

Ronckers CM, Van Leeuwen FE, Hayes RB, Verduijn PG, Stovall M, Land CE. Cancer incidence after nasopharyngeal radium irradiation. Epidemiology 2002; 13: 552-60.

Ronckers CM, Land CE, Hayes RB, Verduijn PG, Stovall M, Van Leeuwen FE. Late health effects of childhood nasopharyngeal radium irradiation: non-melanoma skin cancers, benign tumors and hormonal disorders. Pediatr Res 2002; 52: 850-8.

Hauptmann M, Berhane K, Langholz B, Lubin JH. Using splines to analyse latency in the Colorado Plateau uranium miners cohort. J Epidemiol Biostat 2001; 6: 417–424.

Ronckers CM, Land CE, Verduijn PG, Hayes RB, Stovall M, Van Leeuwen FE. Cancer mortality after nasopharyngeal radium irradiation in the Netherlands: a cohort study. J Natl Cancer Inst 2001; 13: 1021-7.

Hauptmann M, Wellmann J, Lubin JH, Rosenberg PS, Kreienbrock L. The analysis of exposure-timeresponse relationships using a spline weight function. Biometrics 2000; 56: 1105–1108.

Hauptmann M, Lubin JH, Rosenberg PS, Wellmann J, Kreienbrock L. The use of sliding time windows for the exploratory analysis of temporal effects of smoking histories on lung cancer risk. Stat Med 2000; 19: 2185–2194.

Van den Brandt PA, Dirx MJM, Ronckers CM, Van den Hoogen P, Goldbohm RA. Height. Weight, weight change, and postmenopausal breast cancer risk: the Netherlands Cohort Study. Cancer Causes Control 1997; 8: 39-47.

Kontakt

Institut für Biometrie und Registerforschung
Medizinische Hochschule Brandenburg Theodor Fontane
Campus Neuruppin, Haus O
Fehrbelliner Str. 38
16816 Neuruppin

Telefon: +49 3391 39 14581
E-Mail: Sekretariat.Biometrie@mhb-fontane.de